Ibandronate

Half-Life (t½)
PO: 10d · IV: 10d
Formula
C9H23NO7P2
Molecular Weight
319.23 g/mol
PubChem CID
60852
Aliases
Boniva

Pharmacological Mechanism

Aminobisphosphonate — once-monthly oral or once-quarterly IV dosing for postmenopausal osteoporosis. Lower vertebral-fracture-only evidence vs alendronate / risedronate (no demonstrated hip-fracture reduction).

Half-Life & Elimination Curve (PO: 10d · IV: 10d)

100%50%25%12.5%0%0h0×t½10d1×t½20d2×t½30d3×t½40d4×t½50d5×t½0×t½ (0h): 100% remaining (~9.87 µg/L)1×t½ (10d): 50% remaining (~4.94 µg/L)2×t½ (20d): 25% remaining (~2.47 µg/L)3×t½ (30d): 12.5% remaining (~1.23 µg/L)4×t½ (40d): 6.3% remaining (~0.617 µg/L)5×t½ (50d): 3.1% remaining (~0.309 µg/L)
Plasma (PO)t½ Decay (10d)
  • 0×t½0h100% (9.87 µg/L)
  • 1×t½10d50% (4.94 µg/L)
  • 2×t½20d25% (2.47 µg/L)
  • 3×t½30d12.5% (1.23 µg/L)
  • 4×t½40d6.3% (0.617 µg/L)
  • 5×t½50d3.1% (0.309 µg/L)
Elimination t½10d (PO)
Rate Constant (ke)0.00289 h⁻¹
Time to Peak (Tmax)4.43h
Est. Peak (Cmax)9.87 µg/L
Clearance (CL)0.26 L/h
97% Washout (5×t½)50d

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References